CAPOZIDE 25/15 (captopril; hydrochlorothiazide) by Bristol Myers Squibb is clinical pharmacology mechanism of action the mechanism of action of captopril has not yet been fully elucidated. Approved for hypertension, diabetic nephropathy (proteinuria > 500 mg/day) in patients with type i insulin-dependent diabetes mellitus, retinopathy and 8 more indications. First approved in 1984.
Drug data last refreshed 22h ago · AI intelligence enriched 2w ago
CAPOZIDE 25/15 is a fixed-dose combination of captopril (ACE inhibitor) and hydrochlorothiazide (thiazide diuretic) for oral administration. It treats hypertension, heart failure, diabetic nephropathy, and reduces mortality post-myocardial infarction by suppressing the renin-angiotensin-aldosterone system and promoting sodium/fluid loss. The dual mechanism provides synergistic blood pressure reduction and cardioprotection.
Product is approaching loss of exclusivity with legacy market position; commercial team likely managing decline and maximizing remaining branded volume.
CLINICAL PHARMACOLOGY Mechanism of Action The mechanism of action of captopril has not yet been fully elucidated. Its beneficial effects in hypertension and heart failure appear to result primarily from suppression of the renin-angiotensin-aldosterone system. However, there is no consistent…
Worked on CAPOZIDE 25/15 at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on CAPOZIDE offers limited career growth due to LOE-approaching status and generic competition; roles focus on defending market share and managing profitability. Better suited for early-career professionals or those seeking stable, lower-complexity portfolio management before rotating to growth-stage products.